B22: LCK-optoα1AR-IRES-lacZ Strain Information Sheet
Common Name: LCK-optoα1AR-IRES-lacZ
CHROMusTM designation and lines available: R24:B22
Jackson Stock number: NA
Development: The rhodopsin based effector, optoα1AR which on activation generates the second messenger diacylglycerol/IP3, was inserted at the ATG site of the LCK (lymphocyte-specific protein tyrosine kinase) gene in the BAC RP24-159E19 (CHORI) through homologous recombination. The resulting recombinant BAC was injected into the male pronucleus of fertilized oocytes which were then implanted into pseudo pregnant females. Resulting offspring were screened for the presence of the transgene (founders). Colonies were established from each founder and tested for expression.
|# pups born||# founders||# expressors|
Description: The rhodopsin based effector, optoα1AR is expressed under control of the LCK promoter, directing expression to T cells. Expression is observed in spleen. An internal ribosome entry site (IRES) allows for co-expression of lacZ as a visual indicator of expression patterns. This mouse is useful for activating second messengers in T cells.
NOTE: Functional analysis is ongoing. LacZ staining of the spleen shows appropriate expression patterns.
|Expected size of product:||478bp|
So as to appropriately acknowledge and credit the scientists who have produced the LCK-optoα1AR-IRES-lacZ mouse strain, it is expected that you will include these individuals in any publication that is submitted prior to the initial publication of this line from the Kotlikoff laboratory.
Acknowledgement: Please inform us of any publications resulting from the use of this mouse and use the following statement to acknowledge their development:
The mouse strain LCK-optoα1AR-IRES-lacZ was developed by CHROMusTM which is supported by the National Heart Lung Blood Institute of the National Institute of Health under award number R24HL120847.